Replies to post #126661 on Biotech Values

[genisi]

AJ, you're probably right on the low tier journal publication. On a side note, sometimes even the highest tier journal publication cannot make a test to light any fires in terms of revenue like in ROSG' case.
All well at my microcosms level, it's the macrocosm that I'm worried about...